Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson’s Disease?
The fact that Parkinson’s disease (PD) pathologies are well advanced in most PD patients by the time of clinical elucidation attests to the importance of early diagnosis. Our attempt to achieve this has capitalized on our previous finding that GM1 ganglioside is expressed at subnormal levels in virt...
Guardado en:
Autores principales: | Samar K. Alselehdar, Monami Chakraborty, Suman Chowdhury, Roy N. Alcalay, Matthew Surface, Robert Ledeen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a0606aed9acc4f3cac756aa733a7c410 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The structure of gangliosides hides a code for determining neuronal functions
por: Giulia Lunghi, et al.
Publicado: (2021) -
Síndrome anti-GQ1b: Descripción de cuatro pacientes y revisión de la literatura
por: Uribe S.M,Reinaldo, et al.
Publicado: (2013) -
GM3 Ganglioside Linked to Neurofibrillary Pathology in a Transgenic Rat Model for Tauopathy
por: Dominika Olešová, et al.
Publicado: (2021) -
The Association Between Lysosomal Storage Disorder Genes and Parkinson’s Disease: A Large Cohort Study in Chinese Mainland Population
por: Yu-wen Zhao, et al.
Publicado: (2021) -
Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis
por: Shaoyong Wu, et al.
Publicado: (2021)